<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402882</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN15088122</org_study_id>
    <nct_id>NCT01402882</nct_id>
  </id_info>
  <brief_title>Clinical Randomisation of an Antifibrinolytic in Significant Head Injury</brief_title>
  <acronym>CRASH-3</acronym>
  <official_title>Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on
      mortality and disability in patients with traumatic brain injury. The effect of tranexamic
      acid on the risk of vascular occlusive events and seizures will also be assessed.
      Additionally, a nested study will be conducted in a subset of CRASH-3 trial participants.
      This nested study (CRASH-3 Intracranial Bleeding Sub-Study [CRASH-3 IBS]) will examine the
      effect of tranexamic acid on intracranial haemorrhage and cerebral ischaemia using CT Scans
      in approximately 1,000 patients randomised into the CRASH-3 trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Worldwide, over 10 million people are killed or hospitalised because of traumatic
      brain injury (TBI) each year. About 90% of deaths from TBI occur in low and middle income
      countries. TBI mostly affects young adults and many experiencing long lasting or permanent
      disability. The social and economic burden of TBI is considerable. Tranexamic acid (TXA) is
      commonly given to surgical patients to reduce bleeding and the need for blood transfusion.
      TXA has been shown to reduce the number of patients receiving a blood transfusion by about a
      third, reduces the volume of blood transfused by about one unit, and halves the need for
      further surgery to control bleeding in elective surgical patients. More recently, the CRASH-2
      trial showed that the administration of TXA within 8 hours of injury significantly reduces
      deaths due to bleeding (RR=0.85, 95% CI 0.76-0.96; p=0.008), and all-cause mortality
      (RR=0.91, 95% CI 0.85-0.97; p=0.0035), with no apparent increase in vascular occlusive
      events. A meta-analysis of randomised controlled trials of TXA in TBI showed a significant
      reduction in haemorrhage growth (OR=0.61, 95%CI 0.41 to 0.91) and mortality (OR=0.59, 95%CI
      0.35 to 0.99) with TXA. Although the results from these trials are promising, the estimates
      are imprecise and there are no data on the effect of TXA on disability. Additionally, a
      nested study will be conducted in a subset of CRASH-3 trial participants. This nested study
      (CRASH-3 Intracranial Bleeding Sub-Study [CRASH-3 IBS]) will examine the effect of tranexamic
      acid on intracranial haemorrhage and cerebral ischaemia using CT Scans in approximately 1,000
      patients randomised into the CRASH-3 trial.

      AIM: The CRASH-3 trial will provide reliable evidence about the effect of tranexamic acid on
      mortality and disability in patients with TBI. The effect of TXA on the risk of vascular
      occlusive events and seizures will also be assessed.

      PRIMARY OUTCOME: The primary outcome is death in hospital (within 28 days of injury) of
      patients randomised within 3 hours of injury (cause of death will be described).

      SECONDARY OUTCOMES:

        1. Vascular occlusive events (myocardial infarction, stroke, pulmonary embolism, clinical
           evidence of deep vein thrombosis)

        2. In hospital disability assessed using the Disability Rating Scale and Patient Orientated
           Outcome

        3. Seizures

        4. Neurosurgical intervention

        5. Days in intensive care Other adverse events will be described

      Other Outcome Measures: CRASH-3 IBS Primary outcome - the total volume of intracranial
      haemorrhage after randomisation, adjusting for baseline haemorrhage volume.

      Secondary outcome -

        -  Frequency of progressive haemorrhage: number of patients with a post-randomisation CT
           scan with total haemorrhage volume of more than 25% of the volume on the
           pre-randomisation scan;

        -  Frequency of delayed haemorrhage: number of patients with haemorrhage on the
           post-randomisation CT scan when there was not one on the pre-randomisation scan;

        -  New focal ischaemic lesions: ischaemic lesions which appear on the post-randomisation CT
           scan but not on the pre-randomisation scan;

        -  Total volume of intracranial bleeding in patients who undergo surgical evacuation of
           haemorrhage after randomisation, adjusting for volume of baseline bleeding.

      TRIAL DESIGN: A large, pragmatic, randomised, double blind, placebo controlled trial among
      13,000 traumatic brain injury patients

      DIAGNOSIS AND INCLUSION/EXCLUSION CRITERIA:

      Adults with traumatic brain injury who

        -  are within eight hours of injury

        -  with any intracranial bleeding on CT scan or who have a GCS of 12 or less, and

        -  have no significant extra-cranial haemorrhage The fundamental eligibility criterion is
           the responsible clinician's 'uncertainty' as to whether or not to use tranexamic acid in
           a particular patient with traumatic brain injury.

      TEST PRODUCT, REFERENCE THERAPY, DOSE AND MODE OF ADMINISTRATION: A loading dose of
      tranexamic acid

      (1 gram by intravenous injection) or placebo (sodium chloride 0.9%) will be given as soon as
      possible after randomisation. A maintenance dose of tranexamic acid (1 gram by intravenous
      injection) or placebo (sodium chloride 0.9%) will be given after the loading dose is
      finished.

      SETTING: This trial will be coordinated from the London School of Hygiene &amp; Tropical Medicine
      (University of London) and conducted worldwide in hospitals in low, middle and high income
      countries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is death in hospital in patients recruited within 3 hours and cause of death will be described.</measure>
    <time_frame>within 28 days of injury</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(a) Vascular occlusive events (myocardial infarction, stroke, pulmonary embolism, clinical evidence of deep vein thrombosis)</measure>
    <time_frame>Prior death, discharge or 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(b) In hospital disability assessed using the Disability Rating Scale and Patient Orientated Outcome</measure>
    <time_frame>Prior death, discharge or 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(c) Seizures</measure>
    <time_frame>Prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(d) Neurosurgical intervention</measure>
    <time_frame>prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(e) Days in intensive care</measure>
    <time_frame>prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(f) Other adverse events</measure>
    <time_frame>prior death, discharge or day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>CRASH-3 IBS: Primary outcome - the total volume of intracranial haemorrhage</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of progressive haemorrhage: number of patients with a post-randomisation CT scan with total haemorrhage volume of more than 25% of the volume on the pre-randomisation scan</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of delayed haemorrhage:</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New focal ischaemic lesions:</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>â€¢ Total volume of intracranial bleeding in patients who undergo surgical evacuation of haemorrhage after randomisation</measure>
    <time_frame>1) CT scan done before receipt of trial treatment; (2) CT scan done after receipt of trial treatment (up to 28 days after randomisation)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">13000</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Sodium Chloride 0.9%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>2 grams (1 gram over 10 minutes and 1 gram over 8 hours)</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults with traumatic brain injury who

          -  are within eight hours of injury (limited to within 3 hours from September, 2016)

          -  with any intracranial bleeding on CT scan or who have a GCS of 12 or less, and

          -  have no significant extra-cranial haemorrhage The fundamental eligibility criterion is
             the responsible clinician's 'uncertainty' as to whether or not to use tranexamic acid
             in a particular patient with traumatic brain injury

        Exclusion Criteria:

        The fundamental eligibility criterion is the responsible clinician's 'uncertainty' as to
        whether or not to use tranexamic acid in a particular patient with traumatic brain injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haleema Shakur</last_name>
    <role>Study Director</role>
    <affiliation>LSHTM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haleema Shakur, BSc, MSc, RGN</last_name>
    <phone>++44(0)20 7958 8113</phone>
    <email>haleema.shakur@lshtm.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>High Technology Medical Center, University Clinic</name>
      <address>
        <city>Tblisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamar Gogichaishvili</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <link>
    <url>http://crash3.lshtm.ac.uk/</url>
    <description>Trial website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>antifibrinolytic</keyword>
  <keyword>randomised</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Antifibrinolytic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After all relevant publications are completed, totally anonymised data will be available at https://ctu-app.lshtm.ac.uk/freebird/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

